Production of a functional proteome is a major burden for our cells.
Question 1: How Efficient is Protein Folding?
Many (most?) proteins may adopt multiple 'native' conformations (1, 2) . Moreover, the very same gene product may enter different supramolecular complexes, as in the case of P97 (3, 4) , Gp78 (5) or protein disulfide isomerase (PDI) (6) , which may have distinct functions and intracellular localizations. The percentage of nascent chains that eventually attain the native and functional structure or structures, and that will be delivered to the appropriate site of activity, varies dramatically for each gene product and strictly depends on the cell and environmental conditions. Essentially, for most polypeptides, if not all, there is no trustable prediction on the efficiency to attain the functional shape. However, it is assumed that cellular chaperone machineries ensure that folding is efficient for most proteins (7, 8) , even though divergent opinions exist (9, 10) and classical examples of inefficient folders such as the cystic fibrosis transmembrane conductance regulator (CFTR) are described in the literature (11) . Despite the challenges encountered by polypeptides emerging from the ribosome in the living cell, molecular crowding being a major one (12) , folding in vivo is in general much more efficient than protein (re)folding in the more controlled and controllable environment of a test tube (13) .
The fact that protein folding might already start during the synthesis of the polypeptide chain and proceeds vectorially under the assistance of general, as well as specific folding factors, substantially contributes to folding efficiency in the living cell (14) . Regardless of the overall efficiency of protein biogenesis, biosynthetic compartments such as the endoplasmic reticulum (ER), the cytosol and the mitochondria must deal with the presence of non-native www.traffic.dk 341 Figure 1 : Protein folding efficiency in the ER. Newly synthesized polypeptides entering the ER as unfolded chains reach the folded state (in green) and are transported to their site of activity (Export). Misfolded proteins (in red) are selected for destruction (Degradation). Folding efficiency is protein-specific and is represented as a scale that measures the rate of transition between folded versus misfolded states or export versus degradation for each protein.
polypeptides that engage molecular chaperones and that may eventually undergo terminal misfolding with possible deleterious effect on compartmental and cellular proteostasis (15, 16) . Protein misfolding does not only pertain to defective products arising from inherited errors in the genetic material (15) or from the imperfect activity of the nano-machineries translating the genetic information into the polypeptide sequences (17) (18) (19) . As discussed below, it may arise from the non-stoichiometric expression of subunits of multimeric protein complexes. It is also a consequence of the crowded environment where protein folding occurs and where native proteins eventually operate (20) , and of the relatively small free energy of stabilization of folded versus unfolded structures. This latter factor leads to a dynamic equilibrium between folded and unfolded states (Figure 1 ) with the propensity of unfolded conformers to enter aggregates (21) or other irreversible 'off' pathways of folding programs (22) . In this context, the cytosolic proteome is probably at higher risk of misfolding than secretory proteins because the latter tend to be glycosylated and stabilized by inter-and intra-molecular disulfide bonds (23).
Question 2: How are Polypeptide Chains Selected for Destruction?
A major function of the ER is to synthesize proteins that will then function either in the compartment itself, in other cellular organelles, in membranes or in the extracellular space. As such, the ER contains native resident proteins as well as a variety of non-native newly synthesized polypeptides and unpaired subunits of multimeric complexes that do not (yet) fulfill quality control requirements for transport at the site of activity.
Clearance of native proteins
Native, ER-resident proteins are characterized by a physiologic life span that can be short [<3 h for the ER-Associated Degradation (ERAD) factors homocysteine-responsive endoplasmic reticulum-resident ubiquitin-like domain member 1 protein (Herp) (24) and Gp78 (25) ] or very long [for the vast majority of chaperones such as BiP, calnexin and many others (26, 27) ]. It has recently been proposed that modulation of ER-resident factors turnover, especially of those factors such as Herp that have short half-lives, might be part of the first line of response to variations in ER homeostasis. Posttranslational events such as ERAD tuning (i.e., stabilization of short living factors resulting in immediate level increase, regulation of supramolecular complexes' assembly/disassembly (28)), reversible ADP-ribosylation to activate/inactivate chaperone functions (29) , reversible palmitoylation to change chaperone suborganellar distribution (30, 31) allow rapid adaptations of ERAD and folding activities to changes in environmental conditions. The regulated clearance of native proteins plays fundamental roles in ER and cell physiology by modulating, for example, lipid biosynthesis (32) . In this context, the intraluminal level of a rate limiting enzyme in the sterol synthesis (3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR)) inversely correlates with the cellular sterol levels in a posttranslational feedback regulation that relies on HMGCR clearance upon engagement of the E3 ubiquitin-protein ligase synoviolin (SYVN1) and the ubiquitin proteasome system, UPS (33) . Clearance of cellular proteins and presentation at the cell surface of class I major histocompatibility complex (MHC)-associated proteasomal products allows sampling of individual cell's proteome to identify the non-self and thereby the elimination of cells that express mutant or viral peptides (34) . Selection for degradation of native proteins from the ER can also be a consequence of pathogen's attack (Figure 2) . Clearance of class I or class II MHC and CD4 molecules are common strategies adopted by many viruses such as cytomegalovirus, human immunodeficiency virus and hepatitis B virus to evade immunosurveillance (35) .
Clearance of non-native proteins
A major focus of the research in the field is the characterization of mechanisms regulating disposal of polypeptide chains that do not attain the native structure or that do not find their partners in the biosynthetic organelle. Generally, these by-products of protein biogenesis are actively retained in the ER lumen to complete the maturation program. Certain unfolded chains are selected for degradation during or immediately after their synthesis, as in the case of ApoB (36) . Others can spend several hours as immature proteins in the ER without being selected for degradation, as for the gp160 of HIV (37) . The time allocated for folding is characteristic for each gene product. A delay in the folding program may lead to inappropriate destruction of proteins that, if given additional time, would eventually have achieved their functional conformation (22) . Such delays may result from inherited or sporadic mutations of the polypeptide sequence (22, 38) , from non-stoichiometric synthesis of multimeric complex's subunits, for example, due to the gene duplications found in some cancer types (39) or from perturbations in the folding environment. It is crucial to understand the fate of folding-defective polypeptides, i.e. if they are selected for degradation, and in this case, which degradation pathway they engage and why, or if they will undergo aggregation leading to intracellular or extracellular accumulation. In fact, loss-of-function and gain-of-toxic function diseases are direct consequences of disposal or aggregation of mutant polypeptides. Understanding the molecular mechanisms governing these processes allows design of chemical and pharmacologic chaperones that may substantially alleviate disease phenotypes (15, 40) .
Question 3: How are Futile Folding Attempts Interrupted?
The ER produces polypeptides that are co-translationally modified with pre-assembled 14-sugar unit high mannose oligosaccharides on side chains of asparagine (N) residues. It also generates proteins that do not display these N-linked oligosaccharides (41) . All newly synthesized polypeptides are allocated a certain time that they can spend in the lumen of the ER to reach the native conformation (22) . To avoid clogging of the folding compartment with polypeptides that cannot attain a transport-competent structure, folding-defective structures are eventually selected for dislocation across the ER membrane and degradation by cytosolic 26S proteasomes or for delivery to the autolysosomal degradation pathway (42) . For non-glycoproteins, the rules that determine the length of the folding-attempt phase preceding selection for disposal are not known. For N-glycosylated proteins, these rely on the engagement of ER-resident glycosidases that sequentially remove the three terminal glucose residues and two to four α1,2-bonded mannose residues from the protein-bound oligosaccharides (Figure 3) . Removal of mannoses is the true timer that prevents longer retentions of folding-defective proteins in a folding chaperone system named the calnexin/calreticulin/ERp57 folding cycle (41, 43, 44) . Removal of the terminal mannose residue from the central branch B of the polypeptide-bound oligosaccharide possibly facilitates removal of mannose residues from the other two oligosaccharide branches A and C (Figure 4) . Removal of the terminal mannose residue(s) from the branch A impedes the action of the UDP-glucose:glycoprotein glucosyltransferase (UGT1), which is required for retention of folding proteins in the calnexin cycle (Figure 4) (45) . Removal of the terminal mannose from branch C exposes a terminal α1,6-bonded mannose residue that recruits OS-9 and XTP3-B, two ER-resident lectins (Figure 4 ). OS-9 and XTP3-B deliver terminally misfolded proteins to dislocation sites in the ER membrane that are engaged to transport the unfolded cargo into the cytosol for polyubiquitylation and proteasomal degradation (46) (47) (48) (49) . Identification of the ER-resident mannosidases regulating terminal α1,2-bonded mannose removal revealed the enzymatic intervention of one or more members of the glycoside hydrolase 47 family, namely the ER α1,2-mannosidase I (50), EDEM1 (51), EDEM2 (52) and/or EDEM3 (53,54) (Figure 4 ).
Question 4: Who is Degrading Misfolded or Orphan Proteins Produced in the ER?
As far as is known, the ER lumen does not contain proteolytic machineries that are able to clear the biosynthetic organelle of misfolded proteins. For instance, proteases en route for the lysosomal system are made in a pro-form to ensure that they are inactive in the ER (55) . The ER contains, however, putative proteases such as Lonp2 and CPVL that associate with the ERAD lectins OS-9 and XTP3-B to ensure clearance of soluble ERAD substrates (56) . Nevertheless, in current models, soluble polypeptides must be dislocated across the ER membrane and membrane-anchored polypeptides must be extracted from the membrane to be delivered into the cytosol, which contains several proteolytic systems ( Figure 5 ) (see below). The processes of misfolded protein dislocation across the ER membrane or of misfolded protein extraction from the ER membrane are largely unknown and several more or less convincing theories have been proposed from transport through large proteinaceous retrotranslocation channels to the intervention of clipping intramembrane proteases, lipid droplets, extracting factors and others, each one of which may apply to only a subset of misfolded proteins (57-61).
During or after transport into the cytosol, ERAD substrates might undergo polyubiquitylation by a set of at least 24 ER membrane-embedded E3 ubiquitin ligases (62) to be eventually degraded by cytosolic 26S proteasomes ( Figure 5) . Alternatively, if they cannot enter the proteasomal tunnel, or if they undergo aggregation, aberrant polypeptides are engulfed in autophagosomes that deliver them for autolysosomal destruction ( Figure 5 ) (63) . As proteasome inhibitors as well as lysosomotropic drugs only partially and temporarily block the disposal of misfolded polypeptides from the ER, it is likely that many proteolytic systems are engaged contemporarily or can be activated upon blockade of one or the other pathway. In fact the cytosol, or the cytosolic face of organellar membranes contains several proteolytic systems such as the UPS (64, 65) , the autophagic machinery (66, 67) , tricorn protease-like hydrolases (68), calpains (69), Zmpste24 (70) and many others ( Figure 5) . Consistently, at least the UPS and the autophagic pathways are linked by compensatory mechanisms that increase activity of one, when the other is impaired or defective (71-73).
Question 5: What is ERAD for?
The answer appears quite simple: the physiologic role of ERAD is to contribute to the maintenance of ER and cell homeostasis by removing faulty and potentially toxic gene products or subunits of multimeric complexes expressed in non-stoichiometric quantity (35, 60, (74) (75) (76) . The latter might result, for example, from aneuploidy, i.e. abnormal chromosome number with missing or supernumerary genes that may correlate with proteotoxic stress leading to mental retardation or several types of cancer (39, 77, 78) . It is believed that the occurrence of late onset protein misfolding diseases could be related to the age-dependent decline of quality control capacity (79) (80) (81) (82) .
Moreover, ERAD regulates turnover and intracellular content of various functional gene products thereby determining their function at the posttranslational level (35, 61, 64, 74, 76, 83, 84) in processes that can collectively be defined as ERAD tuning (28) .
However, we still do not know most of the endogenous substrates and of the pathways that might be controlled by regulated ERAD or ERAD tuning (28) . Certainly, a few endogenous ERAD substrates have been reported, e.g. the HMGCR (85), Herp (86) and E3 ubiquitin ligases (25, 87) , CD147 (88) and ATF6 (89) , the degradation of which might play important regulatory roles in processes such as sterol synthesis, ERAD, assembly of various multimeric complexes or unfolded protein response (UPR), respectively. The proteolytic activities by cytosolic and nuclear proteasomes or by (auto)lysosomal enzymes, ERAD as well, may eventually generate amino acids to be used for protein biogenesis (90, 91) . Moreover, a fraction of the proteolytic fragments derived from proteasomal activity is imported back into the ER lumen, where, upon trimming by amino peptidases to the appropriate length, they are loaded onto class I MHC and presented at the cell surface (self-reactivity of the immune system). In this manner, CD8 + T cells can recognize and eliminate cells that present viral-or bacterial-derived peptides, as symptoms of pathogenic infection, as well as cells displaying tumor-specific antigens (10).
The importance of the regulatory role of ERAD or of protein degradation in the control of cells or organisms homeostasis appears to clash with the observation that most proteins in Escherichia coli (92) , Saccharomyces cerevisiae (76, (93) (94) (95) (96) and Metazoa cells (27, 97) are extremely stable. Their abundance must therefore be controlled at the translational level (97, 98) and, in the case of supramolecular complexes, cells must know how many molecules of individual complex subunits are needed to eventually assemble the functional protein (76,98) ( Figure 6 ). This is a nice way to spare energy by preventing the production of excessive amounts of subunits that must then be destroyed. However, it should not be forgotten that the modulation of protein turnover could represent, together with other posttranslational modifications (29) , the first line of response to variations in cellular homeostasis requiring regulation of the intracellular level and activity of proteins in the absence of induction of transcriptional programs such as the UPR (35) . According to this hypothesis, the identification of rapidly turned-over ER factors, amongst the bulk of stable proteins (76) , could identify candidate proteins whose expression level can be rapidly enhanced posttranslationally upon regulated prolongation of the half-life.
Which Questions do Remain to be Answered?
There are obviously many questions to be tackled in the future years. Some derive from the imprecise and controversial answers available to the five questions addressed above. Others have to do with the hijacking of ERAD pathways by viral and bacterial pathogens aiming to promote their replication and escape immunosurveillance (99, 100) . Discovering the identity and the mechanisms of hijacked pathways and the molecular components targeted by bacterial toxins or viral gene products will pave the way for the discovery of novel antibacterial or antiviral therapies and may indicate how cancer cells can exploit modulation of degradation activities to acquire resistance to antitumor therapy or higher malignancy. Another question is what signals and which modulators activate the clearance of entire ER portions with their content, a type of ER-specific autophagy defined as ER-phagy (101) , that possibly occurs in many different, still insufficiently appreciated flavors (e.g. to maintain the ER volume, to help it return to the physiologic size at the end of a phase of expansion resulting from stresses, to eliminate subdomains containing inextricable aggregates of misfolded proteins and to provide amino acids in starved cells).
